SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
AbbVie's office in South San Francisco, California
Approvals
AbbVie, Genmab Secure European Label Expansion for Tepkinly in Follicular Lymphoma
Two months after winning FDA approval in the same indication, AbbVie and Genmab on Monday secured the European Commission’s nod for its bispecific antibody Tepkinly for the most common type of low-grade non-Hodgkin lymphoma.
August 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Aerial skyline of Austin
Job Trends
9 Life Sciences Companies Hiring in Texas
Looking for a job in Texas? Check out these nine companies hiring life sciences professionals like you.
August 8, 2024
 · 
1 min read
 · 
Angela Gabriel
exteriors of Merck, Biogen and BMS
Deals
Top I&I Deals So Far in 2024
The size of the global immunology market is projected to nearly double by 2032 to a quarter of a trillion dollars. Here are this year’s standout deals in the space.
August 7, 2024
 · 
5 min read
 · 
Mollie Barnes
Quality control professional examines sample in beaker in laboratory
Career Advice
9 Companies Hiring Quality Control Jobs
Looking for a quality control job? Check out these nine companies hiring life sciences professionals like you.
August 1, 2024
 · 
1 min read
 · 
Angela Gabriel
AbbVie's office in South San Francisco, California
Regulatory
AbbVie’s Skyrizi Wins EU Nod for Ulcerative Colitis, Helps to Weather Humira Patent Cliff
Friday’s European Commission approval is a boost to AbbVie as the company looks to lean on its immunology assets, including Skyrizi, to soften the blow of Humira’s loss of exclusivity.
July 29, 2024
 · 
2 min read
 · 
Tristan Manalac
AbbVie's office in South San Francisco, California
Earnings
Despite Near 30% Drop in Humira Sales, AbbVie Beats Wall Street’s Q2 Revenue Expectations
While Humira sales were impacted by cheaper biosimilars, AbbVie reported in its second-quarter earnings results Thursday that revenues jumped nearly 45% for Skyrizi and almost 56% for Rinvoq year over year, respectively.
July 25, 2024
 · 
2 min read
 · 
Tyler Patchen
Automation engineer works at computer
Career Advice
7 Companies Hiring Automation Engineers
Looking for an automation engineer job? Check out these seven companies hiring life sciences professionals like you.
July 25, 2024
 · 
1 min read
 · 
Angela Gabriel
A brain hovers over a hand against a yellow-striped background
Neuroscience
5 Neuro Data Readouts to Watch in the Second Half of 2024
After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months.
July 15, 2024
 · 
6 min read
 · 
Heather McKenzie
AbbVie's office in South San Francisco, California
Business
AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report
CVS Caremark’s recent decision to take AbbVie’s Humira off its major formularies has caused the blockbuster to lose more market share to biosimilars, according to the latest report from Samsung Bioepis.
July 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
FDA
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
September 27, 2024
 · 
7 min read
Press Releases
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson’s Disease
September 27, 2024
 · 
8 min read
Press Releases
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
September 26, 2024
 · 
23 min read
Press Releases
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
September 20, 2024
 · 
10 min read
Press Releases
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
September 17, 2024
 · 
2 min read
Press Releases
Health Canada Approves AbbVie’s CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age
September 10, 2024
 · 
5 min read
Press Releases
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
September 9, 2024
 · 
18 min read
Press Releases
AbbVie Declares Quarterly Dividend
September 6, 2024
 · 
1 min read
Press Releases
AbbVie’s VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for the Treatment of Schizophrenia
September 4, 2024
 · 
4 min read
News
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
August 27, 2024
 · 
4 min read
Load More